Collegium Pharmaceutical stock, healthcare

Collegium Pharmaceutical stock falls 1.45 percent near yearly low

Published on 09/24/2026 at 07:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Collegium Pharmaceutical stock stood at USD 22.45 on September 23, 2026, 3.7 percent above its 52-week low. Q2 adjusted EPS reached USD 1.92 as revenue grew 6.3 percent.

Collegium Pharmaceutical stock, healthcare, specialty pharmaceuticals, Q2 2026, Nasdaq, Illustration mit AI erstellt.

Collegium Pharmaceutical stock (ISIN US19459J1043) stood at USD 22.45 on Nasdaq on September 23, 2026, down 1.45 percent from the prior close of USD 22.78. The price was 3.7 percent above its 52-week low of USD 21.65, keeping the company close to the bottom of its annual trading range.

Q2 revenue grows 6.3 percent

Collegium reported Q2 2026 revenue of USD 199.9 million, up 6.3 percent year over year, while adjusted EPS reached USD 1.92. According to StockStory, adjusted EPS exceeded the USD 1.77 analyst estimate, while adjusted EBITDA came in at USD 113.8 million.

The result is mixed in composition. JORNAY PM revenue rose 41 percent year over year to USD 46.1 million, but XTAMPZA ER revenue fell 14 percent to USD 45.0 million, according to StockStory.

Guidance sets the next test

Collegium expects 2026 product revenue of USD 825 million to USD 855 million and adjusted EBITDA of USD 445 million to USD 470 million. The range puts execution in the ADHD portfolio alongside pricing pressure in the NUCYNTA franchise at the center of the earnings debate.

The company also has a defined capital-return program. StockTitan.net reports a USD 50 million accelerated share repurchase within a USD 150 million authorization, with 1,556,420 shares initially delivered at USD 25.70.

Oppenheimer targets USD 50

Oppenheimer initiated coverage at Outperform on September 23, 2026, and set a USD 50.00 price target, according to Investing.com. That target is USD 27.55 above the September 23 price, a gap of 122.7 percent, making the analyst view materially more optimistic than the current market valuation.

Collegium Pharmaceutical stock therefore carries two distinct signals on September 23, 2026: a 6.3 percent year-over-year revenue increase and a share price just 3.7 percent above its 52-week low. The next market test is whether the revenue range and ADHD expansion can offset pressure in the pain portfolio.